These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8835052)

  • 1. Drug-associated Guillain-Barré syndrome: a literature review.
    Awong IE; Dandurand KR; Keeys CA; Maung-Gyi FA
    Ann Pharmacother; 1996 Feb; 30(2):173-80. PubMed ID: 8835052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gangliosides and Guillain-Barré syndrome.
    Raschetti R; Maggini M; Popoli P; Caffari B; Da Cas R; Menniti-Ippolito F; Spila-Alegiani S; Traversa G
    J Clin Epidemiol; 1995 Nov; 48(11):1399-405. PubMed ID: 7490603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of post-rubella Guillain-Barré syndrome associated with ulcerative colitis].
    Saito M; Hozumi I; Kawakami A; Tsuji S
    Rinsho Shinkeigaku; 1994 Nov; 34(11):1121-4. PubMed ID: 7729092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions.
    Blum S; McCombe PA
    J Peripher Nerv Syst; 2014 Jun; 19(2):88-103. PubMed ID: 25039604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of hospital discharge data for public health surveillance of Guillain-Barré syndrome.
    Koobatian TJ; Birkhead GS; Schramm MM; Vogt RL
    Ann Neurol; 1991 Oct; 30(4):618-21. PubMed ID: 1789689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.
    Ruts L; Drenthen J; Jacobs BC; van Doorn PA;
    Neurology; 2010 May; 74(21):1680-6. PubMed ID: 20427754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N; Nasar A; Suri MF; Qureshi AI
    J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Guillain-Barrè syndrome (GBS). Implementation of a register of the disease on a nationwide basis. Italian GBS Study Group.
    Beghi E; Bogliun G
    Ital J Neurol Sci; 1996 Oct; 17(5):355-61. PubMed ID: 8933229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guillain-Barré syndrome in south-west Stockholm, 1973-1991, 1. Quality of registered hospital diagnoses and incidence.
    Jiang GX; de Pedro-Cuesta J; Fredrikson S
    Acta Neurol Scand; 1995 Feb; 91(2):109-17. PubMed ID: 7785420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute polyneuritis and polyradiculoneuritis: uncommon causes and their pathomechanisms].
    Duning T; Kraus J; Schäbitz WR
    Fortschr Neurol Psychiatr; 2009 Apr; 77(4):218-27. PubMed ID: 19347793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intravenous immune globulin in the management of severe Guillain-Barre syndrome.
    Baskin E; Turkay S; Icagasioglu D; Tanzer F; Cevit O
    Turk J Pediatr; 1996; 38(1):119-23. PubMed ID: 8819632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guillain-Barré syndrome after influenza vaccination in the United States, a report from the CDC/FDA vaccine adverse event reporting system (1990-2009).
    Souayah N; Yacoub HA; Khan HM; Farhad K; Mehyar LS; Maybodi L; Menkes DL; Qureshi AI
    J Clin Neuromuscul Dis; 2012 Dec; 14(2):66-71. PubMed ID: 23172385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guillain-Barré syndrome in Larimer County, Colorado: a high-incidence area.
    Kaplan JE; Poduska PJ; McIntosh GC; Hopkins RS; Ferguson SW; Schonberger LB
    Neurology; 1985 Apr; 35(4):581-4. PubMed ID: 3982649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guillain-Barré syndrome: clinical features, immune mechanisms, and therapies].
    Nomura K
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1367-9. PubMed ID: 9128414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guillain-Barré syndrome after H1N1 vaccination in the United States: a report using the CDC/FDA Vaccine Adverse Event Reporting System (2009).
    Souayah N; Yacoub HA; Khan HM; Michas-Martin PA; Menkes DL; Maybodi L; Qureshi AI
    Neuroepidemiology; 2012; 38(4):227-32. PubMed ID: 22555646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case-control study of drugs and other determinants as potential causes of Guillain-Barré syndrome.
    Stricker BH; van der Klauw MM; Ottervanger JP; van der Meché FG
    J Clin Epidemiol; 1994 Oct; 47(10):1203-10. PubMed ID: 7722555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of patients with Guillain-Barré syndrome at seven hospitals on the East Coast of Australia.
    Blum S; Reddel S; Spies J; McCombe P
    J Peripher Nerv Syst; 2013 Dec; 18(4):316-20. PubMed ID: 24172315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guillain-Barré syndrome following Campylobacter jejuni enteritis. Report of three cases and review of the literature.
    Sovilla JY; Regli F; Francioli PB
    Arch Intern Med; 1988 Mar; 148(3):739-41. PubMed ID: 3277576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. History of acute polyradiculoneuropathy (part 1): The prehistory of Guillain-Barré syndrome.
    Mathis S; Soulages A; Vallat JM; Le Masson G
    Neurology; 2020 May; 94(19):828-835. PubMed ID: 32345732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.